Tagged with B

Saudi Arabia Amr Seif introduces the evolution in Astellas’ MEA strategy; the adoption of innovative access models to ensure that the companies’ therapies are available for all patients who need them; and the challenges and opportunities in the Saudi pharma market.   We are opening a new chapter in medicine. The early…

Saudi Arabia Emcure’s Senior VP for the Middle East, North & West Africa, Afghanistan, Pakistan & Turkey, Amr El-Neklawy, highlights the level of organizational independence given to his region, the necessity of agility and focus when competing in the generics market, and how the Indian multinational is standing out by offering its…

Global PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work has taken on in the past 12 months. From one of Asia’s leading regulatory bodies to some of the Middle East’s most dynamic emerging companies via…

Global Become a PharmaBoardroom Member for free to access this contentJoin the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password Remember Me Forgot your password? Don't have a PharmaBoardroom account? Create one

Global Become a PharmaBoardroom Member for free to access this contentJoin the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password Remember Me Forgot your password? Don't have a PharmaBoardroom account? Create one

Saudi Arabia Boston Scientific’s general manager for Saudi Arabia, Basel Al-Qahtani, highlights the company’s bet on the country – including the move to a direct presence and the signing of a memorandum of understanding to establish regional headquarters in Riyadh. In addition, he explains the public-private sector dynamics as it relates to…

Mexico The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal antibodies to treat COVID-19 and Bayer’s LatAm general manager comments on providing regional doctors with “the Netflix of medical information”…

Saudi Arabia Saudi Arabia’s response to COVID-19 stands up well to international comparisons in both the MENA region and globally. In recent conversation with PharmaBoardroom, Fahad Al Shebel, CEO of national medicine procurement body NUPCO, outlines some of the fundamentals behind this success story.   Extreme, But Effective, Measures Saudi Arabia took…

Global Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more.   1. United States Way out in first place with a market value of USD 533.5 billion in sales in 2020,…

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

Spain According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends include the fact that generics penetration in Spain has remained at a constant level for almost seven years and private…

China The latest news from Chinese pharma, including an examination of the new national reimbursement drug list (NRDL), the therapies that have and have not made it onto the list, and the significant price cuts that have been agreed. Also included are the World Health Organization (WHO)’s plea to Chinese COVID-19…